These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 38427500)
1. Metabotropic Glutamate Receptor 4 (mGlu4) Positive Allosteric Modulators Lack Efficacy in Rat and Marmoset Models of L-DOPA-Induced Dyskinesia. Finlay CJ; Jackson MJ; Fisher R; Bundgaard C; Rose S; Duty S J Parkinsons Dis; 2024; 14(2):245-259. PubMed ID: 38427500 [TBL] [Abstract][Full Text] [Related]
2. Synergy between L-DOPA and a novel positive allosteric modulator of metabotropic glutamate receptor 4: implications for Parkinson's disease treatment and dyskinesia. Bennouar KE; Uberti MA; Melon C; Bacolod MD; Jimenez HN; Cajina M; Kerkerian-Le Goff L; Doller D; Gubellini P Neuropharmacology; 2013 Mar; 66():158-69. PubMed ID: 22491024 [TBL] [Abstract][Full Text] [Related]
3. Effect of the mGlu Frouni I; Kwan C; Bédard D; Kang W; Hamadjida A; Nuara SG; Gourdon JC; Huot P Psychopharmacology (Berl); 2023 Oct; 240(10):2093-2099. PubMed ID: 37516708 [TBL] [Abstract][Full Text] [Related]
4. Antiparkinsonian Effects of a Metabotropic Glutamate Receptor 4 Agonist in MPTP-Treated Marmosets. Mann E; Jackson M; Lincoln L; Fisher R; Rose S; Duty S J Parkinsons Dis; 2020; 10(3):959-967. PubMed ID: 32250315 [TBL] [Abstract][Full Text] [Related]
10. Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease. Pinna A; Ko WK; Costa G; Tronci E; Fidalgo C; Simola N; Li Q; Tabrizi MA; Bezard E; Carta M; Morelli M Mov Disord; 2016 Apr; 31(4):501-11. PubMed ID: 26871939 [TBL] [Abstract][Full Text] [Related]
11. The multimodal serotonin compound Vilazodone alone, but not combined with the glutamate antagonist Amantadine, reduces l-DOPA-induced dyskinesia in hemiparkinsonian rats. Cohen SR; Terry ML; Coyle M; Wheelis E; Centner A; Smith S; Glinski J; Lipari N; Budrow C; Manfredsson FP; Bishop C Pharmacol Biochem Behav; 2022 Jun; 217():173393. PubMed ID: 35513119 [TBL] [Abstract][Full Text] [Related]
12. Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease. Mela F; Marti M; Dekundy A; Danysz W; Morari M; Cenci MA J Neurochem; 2007 Apr; 101(2):483-97. PubMed ID: 17359492 [TBL] [Abstract][Full Text] [Related]
13. Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease. Hill MP; Ravenscroft P; Bezard E; Crossman AR; Brotchie JM; Michel A; Grimée R; Klitgaard H J Pharmacol Exp Ther; 2004 Jul; 310(1):386-94. PubMed ID: 15004218 [TBL] [Abstract][Full Text] [Related]
14. Pharmacological stimulation of metabotropic glutamate receptor type 4 in a rat model of Parkinson's disease and L-DOPA-induced dyskinesia: Comparison between a positive allosteric modulator and an orthosteric agonist. Iderberg H; Maslava N; Thompson AD; Bubser M; Niswender CM; Hopkins CR; Lindsley CW; Conn PJ; Jones CK; Cenci MA Neuropharmacology; 2015 Aug; 95():121-9. PubMed ID: 25749357 [TBL] [Abstract][Full Text] [Related]
15. Antidyskinetic Effect of 7-Nitroindazole and Sodium Nitroprusside Associated with Amantadine in a Rat Model of Parkinson's Disease. Bortolanza M; Bariotto-Dos-Santos KD; Dos-Santos-Pereira M; da-Silva CA; Del-Bel E Neurotox Res; 2016 Jul; 30(1):88-100. PubMed ID: 27053252 [TBL] [Abstract][Full Text] [Related]
16. Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia. Bezard E; Tronci E; Pioli EY; Li Q; Porras G; Björklund A; Carta M Mov Disord; 2013 Jul; 28(8):1088-96. PubMed ID: 23389842 [TBL] [Abstract][Full Text] [Related]
17. Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson's disease. Kobylecki C; Cenci MA; Crossman AR; Ravenscroft P J Neurochem; 2010 Jul; 114(2):499-511. PubMed ID: 20456008 [TBL] [Abstract][Full Text] [Related]
18. An mGlu4-Positive Allosteric Modulator Alleviates Parkinsonism in Primates. Charvin D; Di Paolo T; Bezard E; Gregoire L; Takano A; Duvey G; Pioli E; Halldin C; Medori R; Conquet F Mov Disord; 2018 Oct; 33(10):1619-1631. PubMed ID: 30216534 [TBL] [Abstract][Full Text] [Related]
19. Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. Johnston TH; Fox SH; McIldowie MJ; Piggott MJ; Brotchie JM J Pharmacol Exp Ther; 2010 Jun; 333(3):865-73. PubMed ID: 20231306 [TBL] [Abstract][Full Text] [Related]
20. Effect of serotonin transporter blockade on L-DOPA-induced dyskinesia in animal models of Parkinson's disease. Fidalgo C; Ko WK; Tronci E; Li Q; Stancampiano R; Chuan Q; Bezard E; Carta M Neuroscience; 2015 Jul; 298():389-96. PubMed ID: 25907446 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]